WO2011160268A1 - 取代苯酚羟基酸酯的磷酸酯化合物、制备方法及在药物中的应用 - Google Patents
取代苯酚羟基酸酯的磷酸酯化合物、制备方法及在药物中的应用 Download PDFInfo
- Publication number
- WO2011160268A1 WO2011160268A1 PCT/CN2010/001601 CN2010001601W WO2011160268A1 WO 2011160268 A1 WO2011160268 A1 WO 2011160268A1 CN 2010001601 W CN2010001601 W CN 2010001601W WO 2011160268 A1 WO2011160268 A1 WO 2011160268A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- carbon chain
- propofol
- group
- ester
- Prior art date
Links
- -1 Phosphoric acid ester compound Chemical class 0.000 title claims abstract description 55
- 150000001261 hydroxy acids Chemical group 0.000 title abstract description 3
- 238000001308 synthesis method Methods 0.000 title abstract 2
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims abstract description 66
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000001412 amines Chemical class 0.000 claims abstract description 8
- 230000000147 hypnotic effect Effects 0.000 claims abstract description 8
- 150000001413 amino acids Chemical class 0.000 claims abstract description 7
- 229910001413 alkali metal ion Inorganic materials 0.000 claims abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- 229910019142 PO4 Inorganic materials 0.000 claims description 19
- 239000010452 phosphate Substances 0.000 claims description 19
- 239000000047 product Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 230000003444 anaesthetic effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000011630 iodine Substances 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 239000000932 sedative agent Substances 0.000 claims description 7
- 230000001624 sedative effect Effects 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- 150000003461 sulfonyl halides Chemical class 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910001508 alkali metal halide Inorganic materials 0.000 claims description 2
- 150000008045 alkali metal halides Chemical class 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 239000013067 intermediate product Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- DRGAZIDRYFYHIJ-UHFFFAOYSA-N 2,2':6',2''-terpyridine Chemical compound N1=CC=CC=C1C1=CC=CC(C=2N=CC=CC=2)=N1 DRGAZIDRYFYHIJ-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- MROCJMGDEKINLD-UHFFFAOYSA-N dichlorosilane Chemical compound Cl[SiH2]Cl MROCJMGDEKINLD-UHFFFAOYSA-N 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000012429 reaction media Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 16
- 206010002091 Anaesthesia Diseases 0.000 abstract description 9
- 230000037005 anaesthesia Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 4
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 2
- 206010039897 Sedation Diseases 0.000 abstract 2
- 230000036280 sedation Effects 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 229960004134 propofol Drugs 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 13
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- LLVCJWMUDNMTMS-UHFFFAOYSA-N butanedioic acid;phenol Chemical compound OC1=CC=CC=C1.OC(=O)CCC(O)=O LLVCJWMUDNMTMS-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- 239000012043 crude product Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000001384 succinic acid Substances 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 4
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- PHOJOSOUIAQEDH-UHFFFAOYSA-N 5-hydroxypentanoic acid Chemical compound OCCCCC(O)=O PHOJOSOUIAQEDH-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004744 fore-foot Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 230000028527 righting reflex Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNRQVMPSJUZXCI-UHFFFAOYSA-L [Na+].[Na+].P(=O)([O-])([O-])O.OC(C(=O)O)CC Chemical compound [Na+].[Na+].P(=O)([O-])([O-])O.OC(C(=O)O)CC DNRQVMPSJUZXCI-UHFFFAOYSA-L 0.000 description 3
- DHMIORPZESXARK-UHFFFAOYSA-L [Na+].[Na+].P(=O)([O-])([O-])O.OC(C(=O)O)CCC Chemical compound [Na+].[Na+].P(=O)([O-])([O-])O.OC(C(=O)O)CCC DHMIORPZESXARK-UHFFFAOYSA-L 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- WENNCMOQIRLXNF-UHFFFAOYSA-N 2-hydroxypentanoic acid phosphoric acid Chemical compound P(O)(O)(O)=O.OC(C(=O)O)CCC WENNCMOQIRLXNF-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000002989 phenols Chemical group 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 0 CC(C)c(cccc1C(C)C)c1OC(*COP(*)(O)=O)=O Chemical compound CC(C)c(cccc1C(C)C)c1OC(*COP(*)(O)=O)=O 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- VTBCRPYJPVGLJO-UHFFFAOYSA-N P(=O)(O)(O)O.OC(C(=O)O)CC Chemical compound P(=O)(O)(O)O.OC(C(=O)O)CC VTBCRPYJPVGLJO-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- ZMJZYXKPJWGDGR-UHFFFAOYSA-N aminosulfamic acid Chemical compound NNS(O)(=O)=O ZMJZYXKPJWGDGR-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- PRDWIYGIOIVMPA-UHFFFAOYSA-N benzene;phthalic acid Chemical compound C1=CC=CC=C1.OC(=O)C1=CC=CC=C1C(O)=O PRDWIYGIOIVMPA-UHFFFAOYSA-N 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- WNZQDUSMALZDQF-UHFFFAOYSA-N isobenzofuranone Natural products C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- UQGPCEVQKLOLLM-UHFFFAOYSA-N pentaneperoxoic acid Chemical compound CCCCC(=O)OO UQGPCEVQKLOLLM-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Definitions
- Phosphate compound substituted phenolic hydroxy acid ester preparation method and application in medicine.
- the compound can be used as a sedative hypnotic and/or anesthetic drug administered intravenously or intravenously.
- Propofol (Propofol, chemical name: 2,6-diisopropylphenol) is a sedative that is currently widely used in the induction, maintenance, and intensive care of general anesthesia. Propofol has the characteristics of rapid onset and fast inactivation. Since its first clinical report in 1977, it has been gradually promoted and applied worldwide. Since the solubility of propofol in water is only 146 mg/L, the currently clinically applied preparation is prepared from 1% propofol, 10% soybean oil, 2. 25% glycerol and 1.2% refined egg yolk lecithin. As a 0/W emulsion, this dosage form is still widely used in countries all over the world.
- disodium edetate is also added as an inhibitor of bacterial growth.
- the formulation is a white emulsion liquid, pH 7.0 is slightly viscous, easy to inject, stable at room temperature, insensitive to light, and encapsulated in ampoules in nitrogen.
- this preparation still has many disadvantages.
- various stabilizers and solubilizers added are inevitably susceptible to some allergic reactions; soybean oil, lecithin, etc.
- propofol succinic acid monoester sodium salt described in WO200213810 is a water-soluble 2,6-diisopropylphenol derivative, but it is unstable in an aqueous solution and also limits water solubility2. Development and application of 6-diisopropylphenol prodrugs. Summary of the invention
- the present invention will first provide a phosphate compound which replaces a phenolic hydroxyester. On the basis of this, the present invention further provides a process for preparing the compound and the use of the compound in medicine.
- the phosphate compound of the substituted phenolic hydroxy acid ester of the present invention has a structure of the formula (I)
- Y is a linear carbon chain of C r4 , preferably the linear carbon chain Y is a saturated carbon chain, in particular, the linear carbon chain Y is -CH 2 -CH 2 - or - CH 2 -CH 2 - CH 2 - is optimal; M 2 is the same or each is hydrogen, an alkali metal ion, a protonated amine or a protonated amino acid.
- the linear carbon chain Y in the structure of the compound of the above formula (I) is in the form of a simple linear carbon chain, and may have at least one H on its carbon chain including a mercapto group, an ethyl group, a cyclopropyl group, A form substituted with a substituent such as a hydroxy group, a thiol group, an amino group or a substituted amino group.
- the compound of the present invention having the structure of the above formula (I) is a compound having a water-soluble property as a propofol prodrug, and the aqueous solution thereof is stable.
- Formulated in a pharmaceutically acceptable solution form as a centrally inhibited drug that exerts sedative, hypnotic and/or anesthetic effects on animals or humans by intravenous or extravascular routes, and is widely present in the body after alkaline phosphatase action in the body.
- the phosphate can be quickly removed and further decomposed to release the substituted phenol structure (propofol) to produce sedative hypnosis and/or anesthetic effect, thereby effectively overcoming the hydroxy group in the substituted phenol structure to be easily oxidized and poorly water-soluble.
- the shortcomings also increase the stability of the prodrug in vitro, and have the characteristics of being stable in vitro and rapidly decomposing into the body.
- the phosphate, hydroxy acid or the corresponding esterified product released by the compound of the formula (I) is not toxic to the human body.
- the phosphate compound of the formula (I) which replaces the phenolic hydroxy acid ester of the present invention can be suitably used as a central inhibitory drug which exerts sedative, hypnotic and/or anesthetic effects on animals or humans by intravenous or extravascular routes. The role and effect.
- a typical preparation method of the above-mentioned substituted phenolic hydroxy acid ester phosphate compound can be carried out by using 2,6-diisopropylphenol (II) as a raw material, and the following steps are carried out:
- a diacid monoester intermediate (IV) of 2,6-diisopropylphenol in addition to the use of the dianhydride compound (III), 2,6-diisopropylphenol (II) and the like can be obtained.
- Molar diacid compound ( ⁇ ) In the presence of an equimolar amount of N,N-dicyclohexylcarbodiimide (DCC) condensing agent and a catalytic amount of 4-diaminopyridine, the precipitate in the reactant is filtered after sufficient reaction at (TC-room temperature) The filtrate is distilled off to obtain the diacid monoester intermediate (IV).
- the crude diacid monoester intermediate (IV) can be further recrystallized from cyclohexane/ethyl acetate or other suitable solvent. , to obtain a refined intermediate (IV).
- the halogenated intermediate (VII) is acidified by esterification with phosphoric acid in the presence of a tertiary amine compound such as triethylamine or pyridine, and further with an alkali metal base or an amine or amino acid having a basic amino group.
- the salt is formed under basic conditions to obtain a phosphate compound in which the target product represented by the formula (I) is substituted for the phenolic hydroxy acid ester.
- the reaction process is as follows:
- the hydrazine in the diacid compound ( ⁇ ) or the dianhydride compound ( III ) in the reaction formula is a linear carbon chain of -4 , of which -CH 2 is preferred. -CH 2 - or - CH 2 - (3 ⁇ 4-(3 ⁇ 4-.
- the sulfonyl halide reagent is generally selected from the group consisting of fluorenyl phthalide or fluorenyl hydrazide, X is a halogen atom, preferably C1; NaX The 'X' in the 'X-, Br- or halogen ion of the plant, may preferably be a plant.
- the target product (I) can be the corresponding hydrogen Or an alkali metal ion, a protonated amine or a protonated amino acid.
- the above preparation process can generally be selected to include dichloromethane, chloroform, carbon tetrachloride, chlorobenzene, benzene, toluene, petroleum ether, cyclohexane, n-hexane, acetonitrile, acetone, DMF, DMS0, tetrahydrofuran, It is carried out in at least one of a plurality of common reaction solvent media such as diethyl ether, triethylamine, and pyridine.
- a general tertiary compound such as pyridine or triethylamine can be usually selected.
- the above formula (I) structure of the present invention replaces the phosphate compound of the phenolic hydroxy acid ester, so that 2,6-diisopropylphenol (propofol) forms a phosphate derivative of the hydroxy acid ester thereof, and Further forming a pharmaceutically acceptable pharmaceutically acceptable salt with a base or a group containing a basic group, improving the water solubility of propofol, and rapidly decomposing it in the body, thereby increasing the stability of the prodrug in vitro, and thus
- the use of central inhibitory drugs that produce sedative, hypnotic and/or anesthetic effects on animals or humans via intravenous or extravascular routes increases the range of applications of propofol prodrugs.
- Fig. 1 is a graph showing the in vitro plasma decomposition of propofol hydroxybutyrate phosphate of the present invention.
- Figure 2 is a graph showing the in vitro plasma in vivo decomposition of propofol hydroxyvalerate phosphate of the present invention.
- the crude solution of 7.5 g of the iodine intermediate (VII) was dissolved in 100 ml of acetonitrile, and then 9 g of 85% phosphoric acid and 13 g of triethylamine were mixed with 50 ml of acetonitrile, and the latter solution was added to the acetonitrile solution containing the crude intermediate (VII).
- the plate was free of raw materials, the reaction was stopped, the solvent was distilled off under reduced pressure, and the residue was mixed with 100 ml of 3N hydrochloric acid to obtain a turbid liquid, and the aqueous layer was extracted several times with 100 ml of dichloromethane solution, and the organic layer was combined.
- the layer was evaporated under reduced pressure to give a crude product (yield) of the yellow ester of yt.
- the crude product was added with a sodium hydroxide solution of decyl alcohol, adjusted to pH 9, and the decyl alcohol was evaporated under reduced pressure.
- 30 ml of ethyl acetate and 15 ml of acetone were added to precipitate a large amount of white solid, which was refluxed at 70 ° C for 10 minutes, and then allowed to stand for cooling.
- the white crystals of the product (I) of propofol ⁇ -hydroxybutyrate was obtained by the white crystals of the product (I) of propofol ⁇ -hydroxybutyrate.
- the succinic acid and 0. 02g were added in an amount of 13.3g of succinic acid and 0. 02g.
- the above iodine product (VII) was dissolved in 100 ml of acetonitrile, and another 9 g of 85% phosphoric acid and 13 g of triethylamine were mixed with 50 ml of acetonitrile, and the latter solution was added to a crude iodine solution in acetonitrile to react at 65 °C.
- the plate is free of raw materials, the reaction is stopped, the solvent is distilled off under reduced pressure, and the residue is mixed with 100 ml of 3N hydrochloric acid to obtain a turbid liquid.
- the aqueous layer is extracted several times with 100 ml of dichloromethane solution, and the organic layer is combined and evaporated under reduced pressure.
- FRR Forepaw Righting Reflex
- the mice were administered with tail vein injection, and the disappearance of Forepaw Righting Reflex (FRR) was used as the endpoint of the anesthesia. The fore paw reflex was restored to the anesthesia recovery index.
- FRR Forepaw Righting Reflex
- the propofol hydroxyvalerate phosphate disodium salt ED 5 of the present invention was 152 mg/kg, 95% confidence interval was 131-161 ⁇ 2 g/kg, and ED 5 was obtained from the DiprivanTM control group. At 5.9 mg/kg, the 95% confidence interval was 5.1 to 7.9 mg/kg. In ED 5 .
- the propofol hydroxyvalerate phosphate disodium salt group of the present invention had a righting reflex disappearance time of 180.8 ⁇ 45.6 seconds and a recovery time of 500.1 ⁇ 114.6 seconds, and its onset time was significantly longer than that of Dipley.
- the DiprivanTM control group (onset time was 19 ⁇ 3 seconds and recovery time was 260.2 ⁇ 121.6 seconds). It is indicated that propofol hydroxyvalerate phosphate disodium salt also has an exact, reversible anesthetic effect.
- the compound of the present invention causes 2,6-diisopropylphenol (propofol) to form a phosphate derivative of a hydroxy acid ester thereof, and further forms a pharmaceutically acceptable drug with a base or a group containing a basic group.
- the use of salt improves the water solubility of propofol and allows it to rapidly decompose in the body, increasing the stability of the prodrug in vitro, thus allowing sedative and hypnotic and/or anesthesia to animals or humans via intravenous or extravascular routes.
- the application of central inhibitory drugs has increased the scope of application of propofol prodrugs, with positive significance and good prospects, and is suitable for industrial applications.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Anesthesiology (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010356056A AU2010356056B2 (en) | 2010-06-23 | 2010-10-13 | Phosphoric acid ester compound of hydroxy acid substituted phenyl ester, synthesis method and medical use thereof |
JP2013515653A JP5650320B2 (ja) | 2010-06-23 | 2010-10-13 | 置換フェノールを含むヒドロキシ酸エステルのリン酸エステル化合物、その製造方法及びそれを用いた中枢抑制薬 |
CA2801818A CA2801818C (en) | 2010-06-23 | 2010-10-13 | Phosphate ester compound of hydroxy acid substituted phenol ester, preparation method and medical use thereof |
US13/702,204 US9243009B2 (en) | 2010-06-23 | 2010-10-13 | Phosphate ester compound of hydroxy acid substituted phenol ester, preparation method and medical use thereof |
EP10853412.4A EP2586785B1 (en) | 2010-06-23 | 2010-10-13 | Phosphoric acid ester compound of hydroxy acid substituted phenyl ester, synthesis method and medical use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102069427A CN101885735B (zh) | 2010-06-23 | 2010-06-23 | 取代苯酚羟基酸酯的磷酸酯化合物、制备方法及在药物中的应用 |
CN201010206942.7 | 2010-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011160268A1 true WO2011160268A1 (zh) | 2011-12-29 |
Family
ID=43071850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/001601 WO2011160268A1 (zh) | 2010-06-23 | 2010-10-13 | 取代苯酚羟基酸酯的磷酸酯化合物、制备方法及在药物中的应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9243009B2 (zh) |
EP (1) | EP2586785B1 (zh) |
JP (1) | JP5650320B2 (zh) |
CN (1) | CN101885735B (zh) |
AU (1) | AU2010356056B2 (zh) |
CA (1) | CA2801818C (zh) |
WO (1) | WO2011160268A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11439653B1 (en) | 2021-03-30 | 2022-09-13 | Epalex Corporation | Fospropofol formulations |
US11478490B1 (en) | 2021-03-30 | 2022-10-25 | Epalex Corporation | Fospropofol formulations |
US11547714B2 (en) | 2020-02-05 | 2023-01-10 | Epalex Corporation | Fospropofol salts, methods and compositions |
US11628178B2 (en) | 2019-03-26 | 2023-04-18 | Epalex Corporation | Fospropofol methods and compositions |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101906039B (zh) | 2010-06-23 | 2013-05-08 | 四川大学华西医院 | 取代苯酚的羟基酸酯化合物、制备方法及在药物中的应用 |
CN102381972B (zh) * | 2011-09-08 | 2013-10-30 | 四川大学华西医院 | 带有酯结构末端的丙泊酚羟基酸酯类化合物及其制备方法和应用 |
CN102391305B (zh) * | 2011-09-08 | 2013-10-02 | 四川大学华西医院 | 丙泊酚羟基酸酯的磷酸酯二钠盐水合物及其制备方法和应用 |
WO2015120821A1 (zh) * | 2014-02-17 | 2015-08-20 | 江苏恩华络康药物研发有限公司 | 一类水溶性丙泊酚衍生物及其用途 |
CN108264459A (zh) * | 2017-01-03 | 2018-07-10 | 天地人和生物科技有限公司 | 麻醉类化合物及其制备方法和在医学上的应用 |
CN108264461A (zh) * | 2017-01-03 | 2018-07-10 | 天地人和生物科技有限公司 | 一种新型麻醉类化合物及其制备方法和在医学上的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000048572A1 (en) * | 1999-02-18 | 2000-08-24 | Supergen, Inc | Phosphocholine linked prodrug derivatives |
CN101633671A (zh) * | 2009-07-13 | 2010-01-27 | 杭州奥默医药技术有限公司 | 一种磷酰基羧酸丙泊酚酯衍生物及制备方法 |
CN101845057A (zh) * | 2009-03-27 | 2010-09-29 | 四川大学 | 取代苯酚的甲缩醛磷酸盐麻醉镇静药用化合物及制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6362234B1 (en) * | 2000-08-15 | 2002-03-26 | Vyrex Corporation | Water-soluble prodrugs of propofol for treatment of migrane |
CN101575349B (zh) * | 2009-06-11 | 2011-07-20 | 中国科学院广州化学研究所 | 一种丙泊酚磷酸酯二钠盐的制备方法 |
CN101716149B (zh) * | 2009-11-30 | 2013-04-10 | 宜昌人福药业有限责任公司 | 一种新的前体药物制剂 |
-
2010
- 2010-06-23 CN CN2010102069427A patent/CN101885735B/zh active Active
- 2010-10-13 AU AU2010356056A patent/AU2010356056B2/en active Active
- 2010-10-13 EP EP10853412.4A patent/EP2586785B1/en active Active
- 2010-10-13 JP JP2013515653A patent/JP5650320B2/ja active Active
- 2010-10-13 US US13/702,204 patent/US9243009B2/en active Active
- 2010-10-13 WO PCT/CN2010/001601 patent/WO2011160268A1/zh active Application Filing
- 2010-10-13 CA CA2801818A patent/CA2801818C/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000048572A1 (en) * | 1999-02-18 | 2000-08-24 | Supergen, Inc | Phosphocholine linked prodrug derivatives |
CN101845057A (zh) * | 2009-03-27 | 2010-09-29 | 四川大学 | 取代苯酚的甲缩醛磷酸盐麻醉镇静药用化合物及制备方法 |
CN101633671A (zh) * | 2009-07-13 | 2010-01-27 | 杭州奥默医药技术有限公司 | 一种磷酰基羧酸丙泊酚酯衍生物及制备方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2586785A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11628178B2 (en) | 2019-03-26 | 2023-04-18 | Epalex Corporation | Fospropofol methods and compositions |
US11547714B2 (en) | 2020-02-05 | 2023-01-10 | Epalex Corporation | Fospropofol salts, methods and compositions |
US11439653B1 (en) | 2021-03-30 | 2022-09-13 | Epalex Corporation | Fospropofol formulations |
US11478490B1 (en) | 2021-03-30 | 2022-10-25 | Epalex Corporation | Fospropofol formulations |
Also Published As
Publication number | Publication date |
---|---|
CA2801818A1 (en) | 2011-12-29 |
AU2010356056A1 (en) | 2013-01-10 |
EP2586785B1 (en) | 2015-12-16 |
CN101885735B (zh) | 2012-09-12 |
EP2586785A1 (en) | 2013-05-01 |
JP5650320B2 (ja) | 2015-01-07 |
JP2013530967A (ja) | 2013-08-01 |
EP2586785A4 (en) | 2014-02-12 |
CA2801818C (en) | 2017-03-28 |
US9243009B2 (en) | 2016-01-26 |
CN101885735A (zh) | 2010-11-17 |
AU2010356056A8 (en) | 2013-05-02 |
AU2010356056B2 (en) | 2015-03-19 |
US20130085120A1 (en) | 2013-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011160268A1 (zh) | 取代苯酚羟基酸酯的磷酸酯化合物、制备方法及在药物中的应用 | |
WO2011160267A1 (zh) | 取代苯酚的羟基酸酯化合物、制备方法及在药物中的应用 | |
KR100277178B1 (ko) | 약리학적 활성을 가진 니트릭 에스테르들과 그들의 제조공정 | |
KR950004960B1 (ko) | 치환된 α-아미노산, 그 제조방법 및 그 것을 함유하는 약학 조성물 | |
FR2522325A1 (fr) | Nouveaux derives aryliques de la piperazine, de l'homopiperazine et de n,n'-dialkyl diamino-1,2 ethane, leur procede de preparation et leur application en therapeutique | |
BRPI0707873A2 (pt) | compostos amida, Éster, tioamida e tiol Éster do Ácido indol-3-carboxÍlico carregando grupos arila ou heteroarila tendo atividade biolàgica antagonista de recptor de esfingosina-1-fosfato (s1p) | |
CH651561A5 (fr) | Derives des nor-tropane et granatane et leur procede de preparation. | |
LU84660A1 (fr) | Nouvelle classe d'amides de l'acide 1-methyl-5-p-toluoylpyrrole,2-acetique | |
WO2008022541A1 (fr) | Dérivés 2,6-diisopropylphénol anesthésique solubles dans l'eau et leur méthode de préparation | |
CH679583A5 (zh) | ||
EP0280603A1 (fr) | Enantiomères de configuration absolue S de dérivés amide de l'amino-3 quinuclidine, leur procédé de préparation et leur application en thérapeutique | |
US4071686A (en) | Novel benzylidene amino-oxyalkyl carboxylic acids and carboxylic acid derivatives | |
JPS60184077A (ja) | 抗炎症性オキシム前駆薬 | |
SU1447283A3 (ru) | Способ получени конденсированных производных @ S-триазина | |
US4041038A (en) | 1-(3-Phenylpropyl)-4-(beta-alkoxyacryloyl)piperazine derivatives | |
US4795758A (en) | 5-[2-(pyrrolidin-1-yl)ethoxy]-p-cymene derivatives, the process for the preparation of the said derivatives and drugs in which the said derivatives are present | |
JP2636013B2 (ja) | ビス(メチレンジオキシ)ビフェニル化合物 | |
US5508280A (en) | 5H-Dibenzo (A,D) cycloheptenes as muscarinic receptor antagonists | |
FR2932480A1 (fr) | Phenyl-alkyl-piperazines ayant une activite modulatrice du tnf | |
JPH0413682A (ja) | カテコール誘導体 | |
CH635335A5 (en) | 2,3-Diphenylchromone derivatives, process for their preparation and their therapeutic application | |
JPS5896051A (ja) | p―アシルアミノフェノール誘導体を含有する鎮痛又は抗炎症薬 | |
PL44426B1 (zh) | ||
CS212520B1 (cs) | Deriváty kyseliny 4-fenyl-2,3-dibrom-1-naftyloxyoctové |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10853412 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13702204 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2801818 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2717/MUMNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2013515653 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010356056 Country of ref document: AU Date of ref document: 20101013 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010853412 Country of ref document: EP |